Anti-NGF Studies Face Major Redesign After Arthritis Advisory Cmte. Urges Resumed Testing

Pfizer’s tanezumab, Regeneron’s REGN475 and Janssen’s fulranumab could head back to the clinic soon, but will need radical protocol changes to protect patients from the emerging risk of joint destruction.